    [United States Statutes at Large, Volume 132, 115th Congress, 2nd Session]
    [From the U.S. Government Publishing Office, www.gpo.gov]

    Public Law 115-411
    115th Congress

    An Act

    To direct the Administrator of the United States Agency for
    International Development to submit to Congress a report on the
    development and use of global health innovations in the programs,
    projects, and activities of the Agency. <>

    Be it enacted by the Senate and House of Representatives of the
    United States of America in Congress assembled, <>
    SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Global Health Innovation Act of
    2017''.
    SEC. 2. ANNUAL REPORT.

    (a) <>  In General.--Not later than 180 days
    after the date of the enactment of this Act, and annually thereafter for
    a period of 4 years, the Administrator of the United States Agency for
    International Development shall submit to Congress a report on the
    development and use of global health innovations in the programs,
    projects, and activities of the Agency.

    (b) Matters To Be Included.--The report required by subsection (a)
    shall include the following:
    (1) A description of--
    (A) the extent to which global health innovations
    described in subsection (a) include drugs, diagnostics,
    devices, vaccines, electronic and mobile health
    technologies, and related behavior change and service
    delivery innovations;
    (B) how innovation has advanced the Agency's
    commitments to achieving an HIV/AIDS-free generation,
    ending preventable child and maternal deaths, and
    protecting communities from infectious diseases, as well
    as furthered by the Global Health Strategic Framework;
    (C) how goals are set for health product development
    in relation to the Agency's health-related goals and how
    progress and impact are measured towards those goals;
    (D) how the Agency's investments in innovation
    relate to its stated goals; and
    (E) progress made towards health product development
    goals.
    (2) How the Agency, both independently and with partners,
    donors, and public-private partnerships, is--
    (A) leveraging United States investments to achieve
    greater impact in health innovation;
    (B) engaging in activities to develop, advance, and
    introduce affordable, available, and appropriate global
    health products; and

    [[Page 5425]]

    (C) scaling up appropriate health innovations in the
    development pipeline.
    (3) A description of collaboration and coordination with
    other Federal departments and agencies, including the Centers
    for Disease Control and Prevention, in support of global health
    product development, including a description of how the Agency
    is working to ensure critical gaps in product development for
    global health are being filled.
    (4) A description of how the Agency is coordinating and
    aligning global health innovation activities between the Global
    Development Lab, the Center for Accelerating Innovation and
    Impact, and the Bureau for Global Health.

    Approved January 3, 2019.

    LEGISLATIVE HISTORY--H.R. 1660:
    ---------------------------------------------------------------------------

    CONGRESSIONAL RECORD, Vol. 164 (2018):
    Jan. 17, 18, considered and passed House.
    Dec. 20, considered and passed Senate.